---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265706"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:32.003689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing

## Summary
- Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).
- Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.
- Phase 3 LUGANO/LUCIA for wet AMD fully enrolled (>900 patients); topline data expected mid-2026, first-to-market target.
- Initiated pivotal Phase 3 DME program (COMO, CAPRI) with FDA non-inferiority pathway; first dosing in Q1 2026.
- Preclinical data shows DURAVYU inhibits IL-6 inflammation plus VEGF, supporting multi-target mechanism in retina.

## SEC filing metadata
- accession: 0001193125-25-265706
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/0001193125-25-265706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/eypt-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265706
- JSON: https://secwatch.observer/filing/0001193125-25-265706.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.